AU2007290881B2 - Candidates against infection - Google Patents
Candidates against infection Download PDFInfo
- Publication number
- AU2007290881B2 AU2007290881B2 AU2007290881A AU2007290881A AU2007290881B2 AU 2007290881 B2 AU2007290881 B2 AU 2007290881B2 AU 2007290881 A AU2007290881 A AU 2007290881A AU 2007290881 A AU2007290881 A AU 2007290881A AU 2007290881 B2 AU2007290881 B2 AU 2007290881B2
- Authority
- AU
- Australia
- Prior art keywords
- plasminogen
- mice
- plg
- bacterial
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82366506P | 2006-08-28 | 2006-08-28 | |
| US60/823,665 | 2006-08-28 | ||
| PCT/SE2007/050585 WO2008026999A2 (en) | 2006-08-28 | 2007-08-28 | Candidates against infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007290881A1 AU2007290881A1 (en) | 2008-03-06 |
| AU2007290881B2 true AU2007290881B2 (en) | 2013-03-07 |
Family
ID=39136397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007290881A Ceased AU2007290881B2 (en) | 2006-08-28 | 2007-08-28 | Candidates against infection |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8318661B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2056864B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5566105B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101517626B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101573134B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007290881B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2662101C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2056864T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA016250B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2451015T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009002226A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008026999A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| NZ597452A (en) | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| WO2011023805A1 (en) | 2009-08-28 | 2011-03-03 | Thrombogenics N.V. | Use of plasmin for the treatment of filtration failure after trabeculectomy |
| RU2421192C1 (ru) * | 2010-03-09 | 2011-06-20 | Винера Гумаровна Нафикова | Способ лечения хронического бактериального конъюнктивита |
| PL2598165T3 (pl) * | 2010-07-26 | 2018-02-28 | Qu Biologics Inc. | Immunogenne kompozycje przeciwzapalne |
| CA2823491A1 (en) | 2011-01-05 | 2012-07-12 | Thrombogenics Nv | Plasminogen and plasmin variants |
| CA2844644A1 (en) | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
| CN102507707B (zh) * | 2011-10-12 | 2015-10-21 | 山东大学 | 一种检测龈沟液中蛋白裂解酶含量的方法 |
| CN106456740B (zh) | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CN106890321A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防和治疗宫颈糜烂的方法 |
| EP3395355B1 (en) * | 2015-12-18 | 2026-03-04 | Talengen International Limited | Plasminogen for use in treating cervical erosion |
| EP3395354B1 (en) * | 2015-12-18 | 2024-05-22 | Talengen International Limited | Plasminogen for use in treating diabetic nephropathy |
| TWI653981B (zh) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
| TWI677347B (zh) * | 2015-12-18 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防和治療肝組織損傷及其相關病症的方法 |
| WO2017101871A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗心血管病的新方法 |
| JP2019500426A (ja) | 2015-12-18 | 2019-01-10 | タレンゲン インターナショナル リミティッドTalengen International Limited | 糖尿病網膜症を予防または治療するための方法 |
| CA3008466C (en) * | 2015-12-18 | 2023-06-20 | Talengen International Limited | Method for preventing or treating radiation and chemical damage |
| JP7213552B2 (ja) * | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| CN108210904A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 治疗动脉粥样硬化及其并发症的药物及其用途 |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| WO2018107701A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种新的降血糖和提高糖耐量的药物 |
| TWI750189B (zh) | 2016-12-15 | 2021-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療冠狀動脈粥樣硬化及其併發症的方法 |
| CA3047170A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating drug-induced renal injury |
| WO2018107689A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂质肾损伤的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN107496911A (zh) * | 2017-10-20 | 2017-12-22 | 滕敏子 | 一种外科手术后用于防肿胀、抗感染的愈合剂 |
| CN113164564A (zh) * | 2018-11-19 | 2021-07-23 | 诺尔玛克Ip股份有限公司 | 用于治疗或预防心内膜炎的安克洛酶 |
| CN114174528B (zh) * | 2019-08-07 | 2025-02-21 | 学校法人东京齿科大学 | 判别方法、荧光测定装置和检查剂 |
| CN111742887A (zh) * | 2019-12-19 | 2020-10-09 | 广西医科大学第一附属医院 | 放疗后分泌性中耳炎树鼩模型的建立方法 |
| EP4094776A4 (en) * | 2020-02-11 | 2023-05-17 | Talengen International Limited | METHODS AND MEDICATIONS FOR THE TREATMENT OF VIRAL PENMONIA |
| WO2021180068A1 (zh) * | 2020-03-09 | 2021-09-16 | 泰伦基国际有限公司 | 一种治疗2019新型冠状病毒引发疾病的方法和药物 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CN115845036B (zh) * | 2023-02-20 | 2023-05-09 | 滨州益洁口腔有限公司 | 用于口腔种植体牙龈组织的蛋白酶及制备方法 |
| JP2026526789A (ja) * | 2023-07-20 | 2026-08-10 | カトリック ユニヴェルシテット ルーヴェン | ブドウ球菌性膿瘍の治療 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| WO2003045466A2 (en) * | 2001-11-26 | 2003-06-05 | Genentech, Inc. | Catheter composition and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3023143A (en) * | 1959-10-14 | 1962-02-27 | American Cyanamid Co | Process for preparing a veterinary composition |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| US5792835A (en) | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| US5397578A (en) * | 1994-03-29 | 1995-03-14 | Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" | Method of treatment of chronic purulent inflammations of ear in children |
| US6372473B1 (en) | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
| US6420622B1 (en) * | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| AU5390699A (en) | 1998-07-24 | 2000-02-14 | Pharmacal Biotechnologies, Inc. | Osseous tissue reconstruction system and method |
| WO2000051538A1 (en) | 1999-03-01 | 2000-09-08 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
| US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| MXPA04007585A (es) * | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| CN1420126A (zh) | 2002-07-10 | 2003-05-28 | 牛勃 | 一种重组人纤溶酶原Kringle5突变体蛋白rhPK-5的制备方法 |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
-
2007
- 2007-08-28 CA CA2662101A patent/CA2662101C/en not_active Expired - Fee Related
- 2007-08-28 US US12/439,517 patent/US8318661B2/en active Active
- 2007-08-28 EA EA200970233A patent/EA016250B1/ru not_active IP Right Cessation
- 2007-08-28 CN CN2007800324051A patent/CN101573134B/zh active Active
- 2007-08-28 AU AU2007290881A patent/AU2007290881B2/en not_active Ceased
- 2007-08-28 EP EP07794195.3A patent/EP2056864B1/en not_active Not-in-force
- 2007-08-28 MX MX2009002226A patent/MX2009002226A/es active IP Right Grant
- 2007-08-28 CN CN200780032092XA patent/CN101563100B/zh not_active Expired - Fee Related
- 2007-08-28 DK DK07794195.3T patent/DK2056864T3/en active
- 2007-08-28 KR KR1020097005738A patent/KR101517626B1/ko not_active Expired - Fee Related
- 2007-08-28 ES ES07794195.3T patent/ES2451015T3/es active Active
- 2007-08-28 WO PCT/SE2007/050585 patent/WO2008026999A2/en not_active Ceased
- 2007-08-28 JP JP2009526572A patent/JP5566105B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-26 US US13/685,466 patent/US20130149321A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,481 patent/US10729750B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| WO2003045466A2 (en) * | 2001-11-26 | 2003-06-05 | Genentech, Inc. | Catheter composition and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| Schott, D et al (1998) The New England Journal of Medicine 339: 1679-1686 * |
| Spier, R et al (1954) Surgery, gynecology & obstretics 98: 667-674 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2662101A1 (en) | 2008-03-06 |
| KR101517626B1 (ko) | 2015-05-07 |
| CN101563100B (zh) | 2013-08-07 |
| JP5566105B2 (ja) | 2014-08-06 |
| EP2056864B1 (en) | 2013-12-11 |
| US20100099600A1 (en) | 2010-04-22 |
| ES2451015T3 (es) | 2014-03-26 |
| US10729750B2 (en) | 2020-08-04 |
| US20160243204A1 (en) | 2016-08-25 |
| EA200970233A1 (ru) | 2009-08-28 |
| CN101573134B (zh) | 2013-03-06 |
| US8318661B2 (en) | 2012-11-27 |
| EP2056864A4 (en) | 2012-01-25 |
| WO2008026999A3 (en) | 2008-05-22 |
| KR20090059122A (ko) | 2009-06-10 |
| CA2662101C (en) | 2015-07-07 |
| US20130149321A1 (en) | 2013-06-13 |
| JP2010502600A (ja) | 2010-01-28 |
| EA016250B1 (ru) | 2012-03-30 |
| WO2008026999A2 (en) | 2008-03-06 |
| AU2007290881A1 (en) | 2008-03-06 |
| CN101563100A (zh) | 2009-10-21 |
| CN101573134A (zh) | 2009-11-04 |
| EP2056864A2 (en) | 2009-05-13 |
| DK2056864T3 (en) | 2014-03-10 |
| MX2009002226A (es) | 2009-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10729750B2 (en) | Candidates against infection | |
| Knight et al. | Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma | |
| Glasser et al. | Mechanisms of lung fibrosis resolution | |
| CN1961958B (zh) | 改善伤口愈合的方法 | |
| DK2056865T3 (en) | Hitherto unknown medicinal products for the prevention and treatment of gum disease, improvement of healing of gums in the gums and promotion of dental and oral health | |
| Zhang et al. | Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats | |
| Gabre et al. | Activated protein C accelerates venous thrombus resolution through heme oxygenase‐1 induction | |
| JP2020023519A (ja) | 異常な皮膚瘢痕化の治療 | |
| TW201731524A (zh) | 一種預防或治療放射性和化學性損傷的方法 | |
| Miao et al. | Staphylococcus aureus on the effect of expression of MMPs/TIMPs and uPA system in bovine mammary fibroblasts | |
| JP2009528339A (ja) | ペプチド及びその使用 | |
| HK1136204A (en) | Candidates against infection | |
| EP3395355B1 (en) | Plasminogen for use in treating cervical erosion | |
| Oliveira et al. | Lack of matrix metalloproteinase-9 impairs neutrophil degranulation and prevents liver damage in mice | |
| JP2013532649A (ja) | 初期免疫防御において新規な機能を発揮する先祖セリンプロテアーゼ凝固カスケード | |
| CN101541829A (zh) | 来自丝光绿蝇的胰凝乳蛋白酶及其在治疗伤口中的用途 | |
| Kostamo | Microbiological, environmental and proteolytic aspects in chronic rhinosinusitis with nasal polyposis | |
| Sacitharan | Linking ageing and arthritis: The role of the longevityrelated SIRT1 molecule in age-related cartilage degeneration and osteoarthritis | |
| CN106890321A (zh) | 一种用于预防和治疗宫颈糜烂的方法 | |
| Blain et al. | British Society for Matrix Biology Meeting, Norwich, 3–4 September 2001 | |
| Hendel | Granzyme B in vascular remodeling and pathological angiogenesis | |
| Gaggar | Protease dysregulation: Role in neutrophilic inflammation in cystic fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |